Jeffrey Wolf is a Clinical Professor at the University of California San Francisco (UCSF) and the Director of the Myeloma Program at the UCSF Helen Diller Family Comprehensive Cancer Center, both in San Francisco, CA.
Prof. Wolf received his medical degree at the University of Illinois Medical Center, Chicago, IL, and completed fellowships in bone marrow transplantation at the Fred Hutchinson Cancer Research Center, Seattle, WA, and in hematology/oncology at UCSF, San Francisco, CA. Additionally, Prof. Wolf helped establish the Bone Marrow Transplant Program at the City of Hope Comprehensive Cancer Center, Duarte, CA, and the first bone marrow transplant unit at Alta Bates Summit Medical Center, Berkley, CA.
Speaking on cancer immunology and hematology
Prof. Wolf specializes in cancers of the bone marrow and blood and bone marrow transplantation to treat these cancers. His primary research focus is on myeloma, specifically on measuring minimal residual disease (MRD) in patients who have undergone successful treatment for myeloma.
Prof. Wolf’s recent research has included being the Principal Investigator for a Phase I clinical trial assessing the safety of a dual TORC1/2 inhibitor in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström’s macroglobulinemia.